Filing Flows › 8-K events › NRX Pharmaceuticals
NRX Pharmaceuticals: regulation fd disclosure
Form 8-K filed Nov 2, 2026 · items 7.01
FDA decisionsNRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date
What the filing says
NRx Pharmaceuticals (Nasdaq:NRXP) Receives FDA Approval of Preservative-Free Ketamine Ahead of November 10 FDA Goal Date manufactured presentation of ketamine that contains no benzethonium chloride (BZT), a toxic antimicrobial preservative that is not Generally Recognized as Safe (GRAS) by the FDA.
Read the filing on SEC EDGAR →
NRX Pharmaceuticals at a glance
Latest quarterQ2 2026
Revenue$1.1M
Operating margin-590.8%
IndustryPharmaceutical Preparations
NRX Pharmaceuticals, Q2 2026: revenue $1.1M, operating margin -590.8%. The chart follows the revenue to costs, profit and cash.
NRX Pharmaceuticals: every quarter, Q/Q and Y/Y, holders and guidance →
Other recent fda decisions
- Biovie Nov 6, 2026
- Acrivon Therapeutics Nov 6, 2026
- Entera Bio Nov 6, 2026
- Precision Biosciences Nov 5, 2026
- Sintx Technologies Nov 5, 2026
- Microbot Medical Nov 5, 2026
- Bioxytran Nov 5, 2026
- Palvella Therapeutics Nov 5, 2026
- ANI Pharmaceuticals Nov 5, 2026
- Teleflex Nov 5, 2026
Read automatically from SEC EDGAR (13F, Form 4, Form 144, Schedule 13D/G, 8-K, XBRL), House and Senate disclosures, FINRA and exchange data; errors are possible. Not investment advice.